2019-01-282019-01-282010-03CARNEIRO, Wilsione Jose; ANDRADE, Carolina Horta; BRAGA, Rodolpho Campos; OLIVEIRA, Valéria de. Identificação da desvenlafaxina, o principal metabólito da venlafaxina, em cápsulas de liberação prolongada. Revista Eletrônica de Farmácia, Goiânia, v. 7, n. 1, p. 39-53, jan./mar. 2010. Disponível em: <https://revistas.ufg.br/REF/article/view/9594/6650>.e- 1808-0804http://repositorio.bc.ufg.br/handle/ri/16877In this work, we describe the identification of desvenlafaxine in extended release capsules of venlafaxine (VEN) in acid degradation studies. We developed a stability indicating reverse-phase HPLC method and validated for the analysis of VEN in pharmaceutical formulation. The HPLC method was linear over the range of 0.45-1.05 mg/ml (r2=0.999). The RSD values for intra- and inter-day precision studies showed good results (RSD < 2%) and accuracy was greater than 99%. The degradation studies in acidic media for 24 h showed two additional peaks, which were further identified by ESI-MS/MS as the desvenlafaxine and the dehydration product of venlafaxine. Furthermore, desvenlafaxine is the major active metabolite of venlafaxine and has recently been approved for treatment of major depressive disorder.porAcesso AbertoEstudos de degradaçãoCápsulas de liberação prolongadaDesvenlafaxinaESIMS/ MSDegradation studiesExtended-release capsulesDesvenlafaxineArtigo10.5216/ref.v7i1.9594